Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

230.60 -3.14 (-1.34%)
Streaming Delayed Price Updated: 12:26 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 199,607
Open 232.65
Bid (Size) 230.36 (100)
Ask (Size) 230.74 (100)
Prev. Close 233.74
Today's Range 230.09 - 233.66
52wk Range 125.38 - 246.90
Shares Outstanding 137,533,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid... 
Via StockStory
Topics Stocks
News headline image
3 Market-Beating Stocks Worth Your Attention
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the... 
Via StockStory

Performance

YTD
+43.6%
+43.6%
1 Month
-3.4%
-3.4%
3 Month
+41.4%
+41.4%
6 Month
+36.5%
+36.5%
1 Year
+45.4%
+45.4%

More News

Read More
News headline image
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Foresight Diagnostics
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
News headline image
3 Cash-Producing Stocks with Solid Fundamentals
Via StockStory
News headline image
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy Government
News headline image
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy
News headline image
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
Via StockStory
Topics Artificial Intelligence
News headline image
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
From Natera, Inc.
Via Business Wire
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Via Benzinga
News headline image
Natera Integrates with Flatiron Health’s OncoEMR® Platform
From Natera, Inc.
Via Business Wire
News headline image
1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds
Via StockStory
Topics Stocks
News headline image
2 Surging Stocks with Impressive Fundamentals and 1 We Question
Via StockStory
News headline image
Natera (NTRA) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase
Via StockStory
News headline image
Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance ↗
Via Chartmill

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?
Yes, Natera, Inc. - Common Stock is publicly traded.
What exchange does Natera, Inc. - Common Stock trade on?
Natera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Natera, Inc. - Common Stock?
The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market
What is the current price of Natera, Inc. - Common Stock?
The current price of Natera, Inc. - Common Stock is 230.60
When was Natera, Inc. - Common Stock last traded?
The last trade of Natera, Inc. - Common Stock was at 12/29/25 12:26 PM ET
What is the market capitalization of Natera, Inc. - Common Stock?
The market capitalization of Natera, Inc. - Common Stock is 31.72B
How many shares of Natera, Inc. - Common Stock are outstanding?
Natera, Inc. - Common Stock has 32B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.